Johnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease

Johnson & Johnson (NYSE: JNJ) announced three-year data from its Phase 3 GALAXI 2 and 3 trials, demonstrating the efficacy and consistent safety profile of TREMFYA (guselkumab) for treating moderately to severely active Crohn's disease. The Week 144 long-term extension results will be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, highlighting clinical and endoscopic outcomes across TREMFYA maintenance regimens.